Risk Behaviors and Risk Factors for HIV Infection among Participants in the Bangkok Tenofovir Study, an HIV Pre-Exposure Prophylaxis Trial among People Who Inject Drugs
Introduction HIV spread rapidly among people who inject drugs in Bangkok in the late 1980s. In recent years, changes in drug use and HIV-associated risk behaviors have been reported. We examined data from the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial conducted among people who inject drugs, to assess participant risk behavior and drug use, and to identify risk factors for HIV infection. Methods The Bangkok Tenofovir Study was a randomized, double-blind, placebo-controlled trial. HIV status was assessed monthly and risk behavior every 3 months. We used generalized estimating equations logistic regression to model trends of injecting, needle sharing, drugs injected, incarceration, and sexual activity reported at follow-up visits; and proportional hazards models to evaluate demographic characteristics, sexual activities, incarceration, drug injection practices, and drugs injected during follow-up as predictors of HIV infection. Results The proportion of participants injecting drugs, sharing needles, and reporting sex with more than one partner declined during follow-up (p<0.001). Among participants who reported injecting at enrollment, 801 (53.2%) injected methamphetamine, 559 (37.1%) midazolam, and 527 (35.0%) heroin. In multivariable analysis, young age (i.e., 20–29 years) (p = 0.02), sharing needles (p<0.001), and incarceration in prison (p = 0.002) were associated with incident HIV infection. Participants reporting sex with an opposite sex partner, live-in partner, casual partner, or men reporting sex with male partners were not at a significantly higher risk of HIV infection compared to those who did not report these behaviors. Conclusion Reports of HIV-associated risk behavior declined significantly during the trial. Young age, needle sharing, and incarceration were independently associated with HIV infection. Sexual activity was not associated with HIV infection, suggesting that the reduction in HIV incidence among participants taking daily oral tenofovir compared to those taking placebo was due to a decrease in parenteral HIV transmission.
References
[1]
Weniger BG, Limpakarnjanarat K, Ungchusak K, Thanprasertsuk S, Choopanya K, et al. (1991) The epidemiology of HIV infection and AIDS in Thailand. AIDS 5 Suppl 2S71–85. doi: 10.1097/00002030-199101001-00011
[2]
Thailand Ministry of Public Health. National AIDS Prevention and Alleviation Committee. UNGASS Country Progress Report, Thailand. Thailand Ministry of Public Health, Department of Disease Control. http://data.unaids.org/pub/ report/2010/thailand_2010_country_progre？ss_report_en.pdf.Accessed 26 December 2013.
[3]
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, et al. (2013) Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381: 2083–2090. doi: 10.1016/s0140-6736(13)61127-7
[4]
Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Chuachoowong R, et al. (2011) Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS One 6: e25127. doi: 10.1371/journal.pone.0025127
[5]
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587–2599. doi: 10.1056/nejmoa1011205
[6]
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367: 399–410. doi: 10.1056/nejmoa1108524
[7]
Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367: 423–434. doi: 10.1056/nejmoa1110711
[8]
Sungkanuparph S, Techasathit W, Utaipiboon C, Chasombat S, Bhakeecheep S, et al. (2010) Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomedicine 4: 515–528.
[9]
Diggle PJ, Liang K, Zeger SL. (1994) Analysis of longitudinal data. Oxford: Oxford University Press.
[10]
Cox DR (1972) Regression models and life-tables. Journal of the Royal Statistical Society Series B (Methodological) 34: 187–220.
[11]
Vanichseni S, Kitayaporn D, Mastro TD, Mock PA, Raktham S, et al. (2001) Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand. AIDS 15: 397–405. doi: 10.1097/00002030-200102160-00013
[12]
Suntharasamai P, Martin M, Vanichseni S, van Griensven F, Mock PA, et al. (2009) Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999–2003. Addiction 104: 235–242. doi: 10.1111/j.1360-0443.2008.02436.x
[13]
Family Health International and Ministry of Public Health Thailand. (2008) The Asian Epidemic Model (AEM) Projections for HIV/AIDS in Thailand: 2005–2025. Available: http://www.gfaidsboe.com/ Downloads/book/2554/AsianEpidemicModelTh？ailand20052025HV.pdf.Accessed 26 December 2013.
[14]
Smith DK, Grohskopf LA, Black RJ, Auerbach JD, Veronese F, et al. (2005) Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 54: 1–20.
[15]
van Griensven F, Varangrat A, Wimonsate W, Tanpradech S, Kladsawad K, et al. (2010) Trends in HIV Prevalence, Estimated HIV Incidence, and Risk Behavior Among Men Who Have Sex With Men in Bangkok, Thailand, 2003–2007. J Acquir Immune Defic Syndr 53: 234–39. doi: 10.1097/qai.0b013e3181c2fc86
[16]
Brewer TF, Vlahov D, Taylor E, Hall D, Munoz A, et al. (1988) Transmission of HIV-1 within a statewide prison system. AIDS 2: 363–367. doi: 10.1097/00002030-198810000-00005
[17]
Taylor A, Goldberg D, Emslie J, Wrench J, Gruer L, et al. (1995) Outbreak of HIV infection in a Scottish prison. BMJ 310: 289–292. doi: 10.1136/bmj.310.6975.289
[18]
Choopanya K, Des Jarlais DC, Vanichseni S, Kitayaporn D, Mock PA, et al. (2002) Incarceration and risk for HIV infection among injection drug users in Bangkok. J Acquir Immune Defic Syndr 29: 86–94. doi: 10.1097/00042560-200201010-00012
[19]
Buavirat A, Page-Shafer K, van Griensven GJ, Mandel JS, Evans J, et al. (2003) Risk of prevalent HIV infection associated with incarceration among injecting drug users in Bangkok, Thailand: case-control study. BMJ 326: 308. doi: 10.1136/bmj.326.7384.308
[20]
Beyrer C, Jittiwutikarn J, Teokul W, Razak MH, Suriyanon V, et al. (2003) Drug use, increasing incarceration rates, and prison-associated HIV risks in Thailand. AIDS Behav 7: 153–161.
[21]
Dolan K, Kite B, Black E, Aceijas C, Stimson GV (2007) HIV in prison in low-income and middle-income countries. Lancet Infect Dis 7: 32–41. doi: 10.1016/s1473-3099(06)70685-5
[22]
Okie S (2007) Sex, drugs, prisons, and HIV. N Engl J Med 356: 105–108. doi: 10.1056/nejmp068277
[23]
Wood E, Montaner J, Kerr T (2005) HIV risks in incarcerated injection-drug users. Lancet 366: 1834–1835. doi: 10.1016/s0140-6736(05)67737-9
[24]
Small W, Kain S, Laliberte N, Schechter MT, O’Shaughnessy MV, et al. (2005) Incarceration, addiction and harm reduction: inmates experience injecting drugs in prison. Subst Use Misuse 40: 831–843. doi: 10.1081/ja-200030795
[25]
Dolan K, Rutter S, Wodak AD (2003) Prison-based syringe exchange programmes: a review of international research and development. Addiction 98: 153–158. doi: 10.1046/j.1360-0443.2003.00309.x
[26]
Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661–1671. doi: 10.1086/508748
[27]
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209–2220. doi: 10.1056/nejmoa0908492
[28]
Wattana W, van Griensven F, Rhucharoenpornpanich O, Manopaiboon C, Thienkrua W, et al. (2007) Respondent-driven sampling to assess characteristics and estimate the number of injection drug users in Bangkok, Thailand. Drug Alcohol Depend 90: 228–233. doi: 10.1016/j.drugalcdep.2007.03.013
[29]
Johnston LG, Prybylski D, Raymond HF, Mirzazadeh A, Manopaiboon C, et al. (2013) Incorporating the Service Multiplier Method in Respondent-Driven Sampling Surveys to Estimate the Size of Hidden and Hard-to-Reach Populations: Case Studies From Around the World. Sex Transm Dis 40: 304–310. doi: 10.1097/olq.0b013e31827fd650
[30]
Konings E, Bantebya G, Carael M, Bagenda D, Mertens T (1995) Validating population surveys for the measurement of HIV/STD prevention indicators. AIDS 9: 375–382. doi: 10.1097/00002030-199509040-00009
[31]
Mastro TD, Kitayaporn D, Weniger BG, Vanichseni S, Laosunthorn V, et al. (1994) Estimating the number of HIV-infected injection drug users in Bangkok: a capture–recapture method. Am J Public Health 84: 1094–1099. doi: 10.2105/ajph.84.7.1094
[32]
World Health Organization. (2009) WHO, UNODC, UNAIDS Technical Guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Available: http://www.unodc.org/ documents/hiv-aids/WHO%20UNODC%20UNAIDS%？20%20IDU%20Universal%20Access%20Target%2？0Setting%20Guide%20-%20FINAL%20-%20Feb%2？009.pdf.Accessed 26 December 2013.
